Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McClellan to think tanks

Executive Summary

Former CMS Administrator Mark McClellan joins the Center for Regulatory Studies, a collaborative program jointly sponsored by the American Enterprise Institute and the Brookings Institution, as a visiting senior fellow. In his joint appointment at the Washington, D.C.-based think tanks, he will work on "the next steps for how I can hopefully continue to have an impact on issues like...the future of Medicare," he says at a Medicare conference sponsored by Avalere in Washington, D.C. Oct. 16. McClellan, who left CMS Oct. 14 after two years as administrator, says he will also continue his academic affiliation with Stanford University. McClellan has been succeeded at CMS by Acting Administrator Leslie Norwalk (1"The Pink Sheet" Sept. 11, 2006, p. 10)...

You may also be interested in...



FDA deputy commissioner resigns

FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb will return to the American Enterprise Institute to work on health policy issues following his resignation from the agency effective Jan. 16. Gottlieb will reunite with Mark McClellan, the former head of FDA and CMS who joined an AEI/Brookings Institution collaborative center last month (1"The Pink Sheet" Oct. 23, 2006, In Brief). Gottlieb served as a senior advisor to McClellan at both agencies...

Next CMS Administrator’s Challenge Will Be Maintaining Part D Momentum

CMS' next administrator will come on board with a key challenge ahead: maintaining Medicare's reputation as a good business partner after initial implementation of the drug benefit, while also satisfying beneficiary advocates and Congress

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel